17 June 2026
17 June 2026
The study aims to enrol about 150 patients across multiple sites.
Completion of the transaction is expected in the fourth quarter of 2026.
The authorisation represents the DEXTER system’s second FDA clearance relating to gynaecology.
In both studies, oveporexton showed improvement at week 12 in daily functioning versus placebo across six FINI domains.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
